Skip to main content

Advertisement

SpringerLink
Log in

Oculopharyngeal muscular dystrophy: A polyalanine myopathy

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

It has been 10 years since the identification of the first PABPN1 gene (GCN)n/polyalanine mutations responsible for oculopharyngeal muscular dystrophy (OPMD). These mutations have been found in most cases of OPMD diagnosed in more than 35 countries. Sequence analyses have shown that such mutations have occurred numerous times in human history. Although PABPN1 was found early on to be a component of the classic filamentous intranuclear inclusions (INIs), mRNA and other proteins also have been found to coaggregate in the INIs. It is still unclear if the INIs play a pathologic or a protective role. The generation of numerous cell and animal models of OPMD has led to greater insight into its complex molecular pathophysiology and identified the first candidate therapeutic molecules. This paper reviews basic and clinical research on OPMD, with special emphasis on recent developments in the understanding of its pathophysiology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Victor M, Hayes R, Adams RD: Oculopharyngeal muscular dystrophy: a familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med 1962, 267:1267–1272.

    Article  PubMed  CAS  Google Scholar 

  2. Tomé FM, Fardeau M: Nuclear inclusions in oculopharyngeal muscular dystrophy. Acta Neuropathol 1980, 49:85–87.

    Article  PubMed  Google Scholar 

  3. Brais B, Bouchard JP, Xie YG, et al.: Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998, 18:164–167.

    Article  PubMed  CAS  Google Scholar 

  4. Brais B, Xie YG, Sanson M, et al.: The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2–q13. Hum Mol Genet 1995, 4:429–434.

    Article  PubMed  CAS  Google Scholar 

  5. Bouchard JP, Brais B, Brunet D, et al.: Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 1997, 7(Suppl 1):S22–S29.

    Article  PubMed  Google Scholar 

  6. Becher MW, Morrison L, Davis LE, et al.: Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 2001, 286:2437–2440.

    Article  PubMed  CAS  Google Scholar 

  7. Duranceau A, Forand MD, Fauteux JP: Surgery in oculopharyngeal muscular dystrophy. Am J Surg 1980, 139:33–39.

    Article  PubMed  CAS  Google Scholar 

  8. Tomé FM, Chateau D, Helbling-Leclerc A, et al.: Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord 1997, 7(Suppl 1):S63–S69.

    Article  PubMed  Google Scholar 

  9. Blumen SC, Brais B, Korczyn AD, et al.: Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol 1999, 46:115–118.

    Article  PubMed  CAS  Google Scholar 

  10. Calado A, Carmo-Fonseca M: Localization of poly(A)-binding protein 2 (PABP2) in nuclear speckles is independent of import into the nucleus and requires binding to poly(A) RNA. J Cell Sci 2000, 113(Pt 12):2309–2318.

    PubMed  CAS  Google Scholar 

  11. Uyama E, Tsukahara T, Goto K, et al.: Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. Muscle Nerve 2000, 23:1549–1554.

    Article  PubMed  CAS  Google Scholar 

  12. Becher MW, Kotzuk JA, Davis LE, et al.: Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. Ann Neurol 2000, 48:812–815.

    Article  PubMed  CAS  Google Scholar 

  13. Abu-Baker A, Messaed C, Laganiere J, et al.: Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003, 12:2609–2623.

    Article  PubMed  CAS  Google Scholar 

  14. Bao YP, Cook LJ, O’Donovan D, et al.: Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 2002, 277:12263–12269.

    Article  PubMed  CAS  Google Scholar 

  15. Calado A, Tomé FM, Brais B, et al.: Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000, 9:2321–2328.

    PubMed  CAS  Google Scholar 

  16. Kim YJ, Noguchi S, Hayashi YK, et al.: The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum Mol Genet 2001, 10:1129–1139.

    Article  PubMed  CAS  Google Scholar 

  17. Corbeil-Girard LP, Klein AF, Sasseville AM, et al.: PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol Dis 2005, 18:551–567.

    Article  PubMed  CAS  Google Scholar 

  18. Robinson DO, Wills AJ, Hammans SR, et al.: Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation. J Med Genet 2006, 43:267–271.

    Article  CAS  Google Scholar 

  19. Nakamoto M, Nakano S, Kawashima S, et al.: Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy. Arch Neurol 2002, 59:474–477.

    Article  PubMed  Google Scholar 

  20. Gurtler N, Plasilova M, Podvinec M, et al.: A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy. Laryngoscope 2006, 116:111–114.

    Article  PubMed  Google Scholar 

  21. Tremolizzo L, Galbussera A, Tagliabue E, et al.: An apparently sporadic case of oculopharyngeal muscular dystrophy: the first Italian report. Neurol Sci 2007, 28:339–341.

    Article  PubMed  CAS  Google Scholar 

  22. Hebbar S, Webberley MJ, Lunt P, et al.: Siblings with recessive oculopharyngeal muscular dystrophy. Neuromuscul Disord 2007, 17:254–257.

    Article  PubMed  Google Scholar 

  23. Semmler A, Kress W, Vielhaber S, et al.: Variability of the recessive oculopharyngeal muscular dystrophy phenotype. Muscle Nerve 2007, 35:681–684.

    Article  PubMed  CAS  Google Scholar 

  24. Messaed C, Dion PA, Abu-Baker A: et al.: Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. Neurobiol Dis 2007, 26:546–557.

    Article  PubMed  CAS  Google Scholar 

  25. Kuhn U, Wahle E: Structure and function of poly(A) binding proteins. Biochim Biophys Acta 2004, 1678:67–84.

    PubMed  CAS  Google Scholar 

  26. Bear DG, Fomproix N, Soop T, et al.: Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore. Exp Cell Res 2003, 286:332–344.

    Article  PubMed  CAS  Google Scholar 

  27. Calado A, Kutay U, Kuhn U, et al.: Deciphering the cellular pathway for transport of poly(A)-binding protein II. RNA 2000, 6:245–256.

    Article  PubMed  CAS  Google Scholar 

  28. Lodderstedt G, Hess S, Hause G, et al.: Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1. FEBS J 2007, 274:346–355.

    Article  PubMed  CAS  Google Scholar 

  29. Lodderstedt G, Sachs R, Faust J, et al.: Hofmeister salts and potential therapeutic compounds accelerate in vitro fibril formation of the N-terminal domain of PABPN1 containing a disease-causing alanine extension. Biochemistry 2008, 47:2181–2189.

    Article  PubMed  CAS  Google Scholar 

  30. Rohrberg J, Sachs R, Lodderstedt G, et al.: Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMR. FEBS Lett 2008, 582:1587–1592.

    Article  PubMed  CAS  Google Scholar 

  31. Sackewitz M, Scheidt HA, Lodderstedt G, et al.: Structural and dynamical characterization of fibrils from a disease-associated alanine expansion domain using proteolysis and solid-state NMR spectroscopy. J Am Chem Soc 2008, 130:7172–7173.

    Article  PubMed  CAS  Google Scholar 

  32. Sackewitz M, von Einem S, Hause G, et al.: A folded and functional protein domain in an amyloid-like fibril. Protein Sci 2008, 17:1044–1054.

    Article  PubMed  CAS  Google Scholar 

  33. Davies J, Wang L, Garcia-Oroz L, et al.: Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005, 6:672–677.

    Article  CAS  Google Scholar 

  34. Davies JE, Sarkar S, Rubinsztein DC: Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2006, 15:23–31.

    Article  PubMed  CAS  Google Scholar 

  35. Ge H, Zhou D, Tong S, et al.: Crystal structure and possible dimerization of the single RRM of human PABPN1. Proteins 2008, 71:1539–1545.

    Article  PubMed  CAS  Google Scholar 

  36. Bao YP, Sarkar S, Uyama E, et al.: Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. J Med Genet 2004, 41:47–51.

    Article  PubMed  CAS  Google Scholar 

  37. Hino H, Araki K, Uyama E, et al.: Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2004, 13:181–190.

    Article  PubMed  CAS  Google Scholar 

  38. Ravikumar B, Duden R, Rubinsztein DC: Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002, 11:1107–1117.

    Article  PubMed  CAS  Google Scholar 

  39. Catoire H, Pasco MY, Abu-Baker A, et al.: Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 2008, 17:2108–2117.

    Article  PubMed  CAS  Google Scholar 

  40. Chartier A, Benoit B, Simonelig M: A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 2006, 25:2253–2262.

    Article  PubMed  CAS  Google Scholar 

  41. Wang Q, Mosser DD, Bag J: Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet 2005, 14:3673–3684.

    Article  PubMed  CAS  Google Scholar 

  42. Verheesen P, de Kluijver A, van Koningsbruggen S, et al.: Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet 2006, 15:105–111.

    Article  PubMed  CAS  Google Scholar 

  43. Berciano MT, Villagra NT, Ojeda JL, et al.: Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus. Hum Mol Genet 2004, 13:829–838.

    Article  PubMed  CAS  Google Scholar 

  44. Villagra NT, Bengoechea R, Vaque JP, et al.: Nuclear compartmentalization and dynamics of the poly(A)-binding protein nuclear 1 (PABPN1) inclusions in supraoptic neurons under physiological and osmotic stress conditions. Mol Cell Neurosci 2008, 37:622–633.

    Article  PubMed  CAS  Google Scholar 

  45. Davies JE, Sarkar S, Rubinsztein DC: Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Hum Mol Genet 2008, 17:1097–1108.

    Article  PubMed  CAS  Google Scholar 

  46. Klein AF, Ebihara M, Alexander C, et al.: PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression. Exp Cell Res 2008, 314:1652–1666.

    Article  PubMed  CAS  Google Scholar 

  47. Pellerin HG, Nicole PC, Trepanier CA, et al.: Postoperative complications in patients with oculopharyngeal muscular dystrophy: a retrospective study. Can J Anaesth 2007, 54:361–365.

    Article  PubMed  Google Scholar 

  48. Mathieu J, Lapointe G, Brassard A, et al.: A pilot study on upper esophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul Disord 1997, 7:S100–S104.

    Article  PubMed  Google Scholar 

  49. Hill ME, Creed GA, McMullan TF, et al.: Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 2001, 124(Pt 3):522–526.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neurogenetics of Motion, Faculty of Medicine, University of Montreal, CHUM Research Center, M-4211-L3, 1560, Sherbrooke East, Montreal, QC, H2L 4M1, Canada

    Bernard Brais

Authors
  1. Bernard Brais
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Brais.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brais, B. Oculopharyngeal muscular dystrophy: A polyalanine myopathy. Curr Neurol Neurosci Rep 9, 76–82 (2009). https://doi.org/10.1007/s11910-009-0012-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-009-0012-y

Keywords

Search

Navigation